A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease. Stem Cell Rev Rep. 2020.
Impact of SARS-CoV-2 in hematopoietic stem cell transplant and CAR-T cell therapy recipients. Transplant Cell Ther. 2021.